drugset / Trial / NCT04122040

Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis

NCT04122040

Phase 3 Completed 40 enrolled Prince of Songkla University
RandomizedParallel-groupSingle-blindTreatment

Summary

roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological outcomes in bronchiectasis

Timeline

Start
2011-03-01
Primary completion
2011-09-30
Completion
2011-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator roxithromycin Small molecule 300 mg Oral

Indications

No indication recorded.